Boston, MA 05\/23\/2014 (wallstreetpr) \u2013 Investment brokerage Goldman Sachs Group Inc (NYSE:GS)<\/b> expects medical technology company, Medtronic, Inc. (NYSE:MDT)<\/b> to accelerate revenue growth in the fiscal year 2015 on FXN basis. The investment advisor has, however, left the rating unchanged for the stock.<\/p>\n
Growth Uptick<\/b><\/p>\n
The investment advisor has retained its fiscal year 2015 as improvement in revenue growth. The brokerage sees 90 basis points acceleration on an FXN basis and believes that its outlook appears to be a re-invigorated one by speeding up the emerging markets uptick going by the trend witnessed in third and fourth quarter. While the company generated 14% growth on FXN in fourth quarter, it was 12% in the third quarter despite some headwinds in Eastern Europe.<\/p>\n
Goldman Sachs Group Inc (NYSE:GS) analyst David Roman believes that new product launches in multiple categories could very well take the company to accelerated growth path, since hospital solutions business contributions could also witness an uptick.<\/p>\n
Though the investment advisor is encouraged by the revenue model forecast for the fiscal year 2015, the general perception is whether the company will be in a position to take advantage of its position in a consolidating consumer scenario. However, the analyst views that Medtronic could influence its entire portfolio, since it has seen previous case studies to display its potential.<\/p>\n
The brokerage is worried that the company\u2019s growth pace has lagged mature, since Medtronic, Inc. (NYSE:MDT) lags behind its peers by 1 \u2013 2 percentage points. Therefore, the analyst is looking forward to the company\u2019s June 5 analyst meeting to get an update on its priorities.<\/p>\n
Rating of Stock<\/b><\/p>\n
Goldman Sachs Group Inc (NYSE:GS) has revised its model for increased revenue from Cardiocom and hospital solutions, more contributions from CRM product launches in the U.S., lower share count, and margin progression. Yet, the brokerage prefers to maintain its Buy rating on attractive valuation. It has kept a 12-month price target of $68 and sees cost management, pipeline development, and competitive dynamics as the key risk factors.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 05\/23\/2014 (wallstreetpr) \u2013 Investment brokerage Goldman Sachs Group Inc (NYSE:GS) expects medical technology company, Medtronic, Inc. (NYSE:MDT) to accelerate revenue growth in the […]<\/p>\n","protected":false},"author":32,"featured_media":23176,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1942,2236],"tags":[3491,1865,3022,3021,734,1022],"stock_ticker":[],"class_list":["post-23409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-banking","category-business","tag-goldman-sachs-group-inc","tag-goldman-sachs-group-inc-nysegs","tag-medtronic-inc","tag-medtronic-inc-nysemdt","tag-nysegs","tag-nysemdt","entry"],"acf":[],"yoast_head":"\n